PARAGON
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety. LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction
- Stage
- klaar
- Medicine
- LCZ696
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 22 December 2014
- Last Patient In
- 14 November 2016
- Last Patient Last Visit
- 22 May 2019
National Lead
prof. dr. D.J. van Veldhuisen
Study Director
